LONDON (ShareCast) - (ShareCast News) - Manchester based molecular diagnostics firm Genedrive announced on Monday it had achieved CE certification for its Hepatitis C assay.
The CE marking, which indicates conformity with health, safety, and environmental protections standards in the European Economic Area, allows for the introduction of Genedrive's assay into Europe and several other countries that accept the certification.

Genedrive chief executive David Budd said: "It is an exciting achievement to be the first company to launch a molecular HCV test designed to be used in smaller hospital laboratories and clinics. CE Marking will allow us to engage with many of the countries where HCV is an endemic healthcare issue."

The Hepatitis C assay is performed on the Genedrive instrument, a diagnostics system aimed at providing molecular analysis at the point of need, providing results within 90 minutes from lyophilised polymerase chain reaction reagents.

"The combination of national screening programs, the availability of cost effective treatment, and consequently a growing demand for molecular diagnostics is an area we can contribute to in a meaningful way," said Budd.

As of 0945 BST, Genedrive shares had moved forward 2.90% to 35.50p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE